Procarbazine Hydrochloride Drug Due Diligence Report 2026

This Procarbazine Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Procarbazine Hydrochloride can convert its Small molecule drug profile and DNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Procarbazine Hydrochloride (query alias: procarbazine)
Modality / target	Small molecule drug; DNA; DNA inhibitors
Highest global status	Approved
Originator	Sigma-Tau BV
Active developers	Sigma-Tau Industrie Farmaceutiche Riunite SpA, Leadiant Biosciences, Inc., Zhaoke Pharmaceutical (Hefei) Co., Ltd.

The MCP disease footprint includes Brain Cancer, Hodgkin's Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07015242	Phase 2	Recruiting	65	Progression-free Survival (PFS)
KCT0009643	Phase 2	Recruiting	40	Not disclosed
JPRN-jRCT1031250745	Phase 2	募集中	16	5年無増悪生存期間（5-year progression-free survival, 5y-PFS）。一次登録日を起算日とし、RANO 2.0基準に基づき腫瘍増悪または死亡をイベントとする。評価期間は登録後5年間とする。

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

POOR PERFORMANCE STATUS MAY PRECLUDE THE USE OF RITUXIMAB, METHOTREXATE, PROCARBAZINE, AND VINCRISTINE IN INDUCTION THERAPY OF PRIMARY CNS DLBCL: A SINGLE-CENTER EXPERIENCE

Not Applicable; n=21; evaluation: Negative. Reported fields: CR = 40.0 %

TREATMENT OUTCOMES FOR PATIENTS WITH PRIMARY CNS LYMPHOMA. DATA FROM A SINGLE-CENTER STUDY

Not Applicable; n=90; evaluation: Positive. Reported fields: -; -; -

QOL-29. PREVALENCE, MANAGEMENT, AND OUTCOMES OF PROCARBAZINE-ASSOCIATED HYPERSENSITIVITY REACTIONS IN PATIENTS RECEIVING PCV FOR LOW-GRADE GLIOMA

Not Applicable; n=61; evaluation: not stated. Reported fields: Adverse Event: anaphylaxis = Three patients with HSRs presented to the emergency department with concern for anaphylaxis, and one required treatment with epinephrine

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Procarbazine Hydrochloride addresses Brain Cancer, Hodgkin's Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-05-01	李氏大药厂与Leadiant Biosciences签订协议引进产品纳治良® 成功在中国上市	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Lipid nanoparticles and uses thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO